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Pancreatic islet b cell mass expands in response to certain physiological conditions such as pregnancy and
obesity, but the signaling pathways involved are not well understood. Possible insights come from a newly
described regulatory circuit through which obesity-enhanced kinase signaling in the liver triggers expansion
of islet mass and enhanced insulin secretion.In type 1 diabetes, the insulin-producing
b cells of the islets of Langerhans are de-
stroyed by autoimmune attack. In obesity
leading to type 2 diabetes, b cell mass first
expands to compensate for insulin resis-
tance in the pre-diabetic phase, followed
by a gradual loss of b cell mass and func-
tion that heralds the onset of hypergly-
cemia (Muoio and Newgard, 2008). Given
the central role of loss of b cells in the
etiology of both major forms of diabetes,
there is growing interest in understanding
pathways of islet regeneration. In a new
study, Imai et al. describe a circuit by
which signals generated in the liver are
propagated via the central nervous
system (CNS) to stimulate expansion of
b cell mass (Imai et al., 2008).
Islet b cell mass expands under certain
physiological conditions such as preg-
nancy or obesity (Muoio and Newgard,
2008;Sorenson and Brelje, 1997). Interrup-
tion of insulin signaling via knockout of the
insulin receptor in liver, but not muscle or
fat, results in expansion of b cell mass
and hyperinsulinemia (Michael et al., 2000),
which when coupled to older reports of
changes in b cell mass in response to
vagotomy and vagal hyperactivity (Edvell
and Lindstrom, 1998; Kiba et al., 1996)
suggests the existence of a liver-pancreas
regulatory circuit. Based on this founda-
tion, Imai et al. reasoned that proteins
that are upregulated in liver in response to
obesity might trigger neuronal signals for
expansion of b cell mass.
Extracellular regulated kinase (ERK),
a signaling protein best known for medi-
ating cellular responses to mitogens and
inflammatory agents, was found to be
upregulated in liver in both genetic, lep-
tin-deficient (ob/ob) and dietary (high-fat-diet fed) mouse models of obesity. To
mimic the effects of obesity on ERK ac-
tivation, the authors used recombinant
adenovirus todeliveraconstitutivelyactive
mutant of mitogen-activated protein
kinase/ERK kinase (MEK-1) (referred to
as CAM) to the livers of normal mice (Imai
et al., 2008). Remarkably, CAM expres-
sion led to better glucose tolerance and
increased insulin secretion in response to
a glucose bolus and a marked increase in
BrdU incorporation (an index of cellular
replication) only 3 days after viral injection.
This was accompanied by increases in
islet mass and pancreatic insulin content,
but these did not become significant
until 11–15 days after viral injection. The
curious discrepancy between the marked
improvement in glucose tolerance and
insulin secretion 3 days after viral injection
and the much slower increase in pancre-
atic insulin content and b cell mass is not
addressed by the authors and suggests
that an increase in islet function by
unknown mechanisms may constitute the
first response to hepatic CAM expression.
To investigate the role of neuronal
signaling in liver-directed islet cell expan-
sion, the authors performed a series of
experiments to reveal that pancreatic
vagotomy, midbrain transection, or chem-
icalblockadeof splanchnicnervesignaling
with capsaicin prevented the improve-
ment in insulin secretion, glucose toler-
ance, and pancreatic insulin content,
whereas hepatic vagotomy or celiac vagus
dissection had no effects. Collectively,
these results suggest that CAM expres-
sion generates signals for islet expansion
that are transmitted via the splanchnic
nerve to the CNS and then to islets via
the pancreatic vagus nerve (Figure 1).Cell MetabolisThe authors also investigated the rele-
vance of liver-islet signaling in obesity-
induced islet expansion and diabetes.
This was accomplished by expression of
a dominant-negative version of MEK-1
(termed DNM) to suppress hepatic ERK
phosphorylation in livers of ob/ob and
high-fat-diet fed mice. Expression of
DNM blunted obesity-induced increases
in pancreatic insulin content in both
models, and pancreatic vagotomy or
capsaicin treatment had similar effects.
They also studied the impact of activation
of liver-islet signaling in two experimental
models of type 1 diabetes, in which
b cell ablation was achieved either
genetically via induction of ER stress in
the Akita mouse or pharmacologically
with the b cell cytotoxin streptozotocin.
Hepatic CAM expression in either model
resulted in a dramatic lowering of blood
glucose within 4 days, whereas insulin
content was significantly increased at
16 days.
Identification of networks that cause
expansion of functional b cell mass is an
important goal in diabetes research, and
this new study provides an outline of
such a pathway. An impressive feature
of the work is the consistency of b cell
adaptive responses that are obtained
across a wide array of animal models
and conditions. However, many ques-
tions are raised.
First, why are the most dramatic effects
on blood glucose and insulin secretion
seen at very early time points after CAM
expression, long before the maximal
effect on insulin content and islet mass
has occurred? An explicit example of
this are the studies in the type 1 diabetes
models, where maximal glucose control ism 9, January 7, 2009 ª2009 Elsevier Inc. 5
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Previewseral insulin sensitivity (Uno et al., 2006),
leaving open the possibility that dual
circuits of liver signaling could be acti-
vated to help control blood glucose.
More knowledge of these systems will
be required before firm conclusions about
therapeutic relevance can be made.
Finally, there are a number of open
questions regarding mechanisms under-
lying the proposed liver-islet circuit,
including (1) How does ERK activation
generate a neuronal signal? (2) What is
the nature of this signal and how is it
received at the level of the islet? (3)
What signaling pathways are activated in
islets in response to the neuronal signal?
Because chronic stimulation of b cell
replication often results in loss of b cell
function (Hohmeier and Newgard, 2005),
the long-term consequences of activation
of the liver-islet circuit must also be care-
fully assessed. In short, while intriguing,
this paper seems to raise nearly as many
questions as it answers.
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Figure 1. Obesity-Activated Liver-Islet Signaling Circuit
An obesity-activated liver-islet signaling circuit described by Imai et al. (2008), in which activation of ERK
signaling in liver leads to expansion of islet cell mass and increased insulin secretion.achieved at day 4, a time point at which no
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